DOCSLIB.ORG

Virtual CROI 2021 Schedule at a Glance Version 3 (Short)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

virtual CROI 2021 Schedule at a Glance Version 3 (Short) LIVE PROGRAM TIME SATURDAY, MARCH 6, 2021 SUNDAY, MARCH 7, 2021 10:00 AM W-1 PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES OPENING SESSION (10:00 – 12:05) EST (10:00 – 14:00) CHAIRS WELCOME TO virtual CROI 2021 START Conveners: Serena S. Spudich and Nicolas Chomont Chairs: Sharon L. Hillier, James A. Hoxie, and Elaine J. Abrams ADVANCES IN MOLECULAR VIROLOGY OF HIV AND SARS-CoV-2 MARTIN DELANEY PRESENTATION LIVE PROGRAM Frank Kirchhoff INTRODUCTION ADVANCES IN HIV AND SARS-CoV-2 IMMUNOLOGY James Pickett Galit Alter VACCINE NATIONALISM IS KILLING US: HOW INEQUITIES IN RESEARCH AND ACCESS TO SARS-CoV-2 VACCINES WILL PERPETUATE THE PANDEMIC ADVANCES IN COVID-19 TREATMENT STRATEGIES AND CONTROLLING THE EPIDEMIC Gregg S. Gonsalves and Fatima Hassan Jürgen Rockstroh BERNARD FIELDS LECTURE ADVANCES IN BIOMEDICAL PREVENTION OF HIV INTRODUCTION Jean-Michel Molina James A. Hoxie and Galit Alter ADVANCES IN HIV CURE NEUTRALIZING ANTIBODIES AGAINST CORONAVIRUSES Katherine J. Bar Pamela J. Bjorkman N'GALY-MANN LECTURE INTRODUCTION Elaine J. Abrams and Tedros Adhanom Ghebreyesus LESSONS FROM THE CONCURRENT HIV/AIDS AND COVID-19 PANDEMICS: A TWO-WAY STREET Anthony S. Fauci 12:20 PM CONCURRENT WORKSHOPS (12:20 – 2:20) EST W-2 FRONTIERS IN LABORATORY TECHNOLOGIES Conveners: Galit Alter and Frank Kirchhoff STRUCTURES OF SARS-CoV-2 ANTIBODIES INDUCED BY INFECTION AND mRNA VACCINES Christopher O. Barnes EMERGING CONCEPTS IN HIV-1 RESTRICTION Edward Campbell SARS-CoV-2 SPECIFIC AND CROSS-REACTIVE T CELL RESPONSES Daniela Weiskopf ARTIFICIAL INTELLIGENCE-INSPIRED ANTIBODY ENGINEERING Sai Reddy W-3 CLINICAL TRIAL DESIGN AND ANALYSIS Conveners: Susan P. Buchbinder and Richard E. Chaisson MAKING SENSE OF STUDY DESIGN DIFFERENCES BETWEEN COVID-19 PLATFORM TRIALS Lori Dodd DESIGN OF CURRENT AND FUTURE COVID-19 VACCINE EFFICACY TRIALS Holly Janes W-4 CASE TRACING AND CASE MANAGEMENT: COVID-19 WORKSHOP Conveners: Robert T. Schooley and David L. Thomas RAPID GENOMIC SEQUENCING FOR MANAGEMENT OF COVID-19 Kwok-Yung Yuen COVID-19: A HOSPITALISED UNWELL PATIENT WITH PNEUMONITIS Sanjay Bhagani CRITICAL CARE OF COVID-19 Janhavi Athale LIVE PROGRAM Last Updated on March 4, 2021 LIVE PROGRAM TIME MONDAY, MARCH 8, 2021 TUESDAY, MARCH 9, 2021 WEDNESDAY, MARCH 10, 2021 10:00 PLENARY SESSION (10:00 – 11:00) PLENARY SESSION (10:00 – 11:00) PLENARY SESSION (10:00 – 11:00) AM EST Session Hosts: Wesley Sundquist and Carlos del Rio Session Hosts: Peter W. Hunt and Sharon L. Hillier Session Hosts: Nicolas Chomont and Elaine J. Abrams START WELCOME AND DAILY ROADMAP WELCOME AND DAILY ROADMAP WELCOME AND DAILY ROADMAP Sharon L. Hillier Elaine J. Abrams James A. Hoxie P-1 IMAGING VIRAL LIFE CYCLES P-3 HIV-1 bNAbs: LOOKING AHEAD P-5 ELITE CONTROLLERS: A MODEL FOR A FUNCTIONAL CURE OF HIV-1 INFECTION Hans-Georg Kräusslich Marina Caskey Xu Yu P-2 DISPARITIES IN HEALTH: FROM HIV TO COVID-19 AND BEYOND P-4 SUSTAINED DELIVERY AND LONG-ACTING AGENTS FOR PREVENTION OF HIV P-6 HIV TREATMENT IN PREGNANCY: BEYOND PREVENTION OF VERTICAL TRANSMISSION James E. Hildreth Linda-Gail Beker Shahin Lockman LIVE PROGRAM 11:15 AM CONCURRENT ORAL ABSTRACT SESSIONS (11:15 – 1:15) CONCURRENT ORAL ABSTRACT SESSIONS (11:15 – 1:15) CONCURRENT ORAL ABSTRACT SESSIONS (11:15 – 1:15) EST O-1 HIV/SIV HOST AND CELLULAR INTERCTIONS: VIROLOGY, IMMUNOLOGY, AND PATHOGENESIS O-5 SARS-CoV-2 VS HOST: VIROLOGY, IMMUNOLOGY, AND PATHOGENESIS O-10 HIV RESERVOIRS Oral Abstract Moderators: John M. Coffin and Richard A. Koup Oral Abstract Moderators: Wesley I. Sundquist and Guido Silvestri Oral Abstract Moderators: Douglas D. Richman and Katharine J. Bar DECIPHERING THE HOST NUCLEUS SUBVERSION BY HIV-1 TO REPLICATE IFITM PROTEINS PROMOTE SARS-CoV-2 INFECTION IN HUMAN LUNG CELLS INFECTED CELLS ARE CLONOTYPICALLY DIVERSE IN BLOOD & LYMPH NODES SINCE FIEBIG STAGE I Francesca Di Nunzio Caterina Prelli Bozzo Pierre Gantner HIV-1 CAPSID RETAINS ITS INTEGRITY UNTIL MINUTES BEFORE UNCOATING IN THE NUCLEUS SARBECOVIRUS ORF6 PROTEINS ANTAGONIZE INTERFERON SIGNALING EVOLUTIONARY DYNAMICS OF HIV RESERVOIR CELLS VIA A NOVEL SINGLE-CELL MULTIOMICS ASSAY Chenglei Li Izumi Kimura Kevin B. Einkauf TRAFFICKING OF HIV-1 ENVELOPE TO THE EHD1/MICAL-L1 TUBULAR-SORTING ENDOSOME SEVERE COVID-19 IS FUELED BY DISRUPTED GUT BARRIER INTEGRITY NONINVASIVE PLASMA GLYCOMIC AND METABOLIC BIOMARKERS OF POSTTREATMENT HIV CONTROL Paul Spearman Leila B. Giron Leila B. Giron A COMPREHENSIVE CRISPR SCREEN FOR HIV DEPENDENCY FACTORS SARS-CoV-2 PERSISTS IN INTESTINAL ENTEROCYTES UP TO 7 MONTHS AFTER SYMPTOM RESOLUTION PD-1 BLOCKADE ENHANCES THERAPEUTIC BENEFITS OF VACCINE IN A CHRONIC SIV/MACAQUE MODEL Vanessa R. Montoya Minami Tokuyama Sheikh A. Rahman EARLY bNAb THERAPY IN SHIVAD8-EO–INFECTED RHESUS MACAQUES COVID-19 OUTCOME: INSIGHTS FROM QUANTIFICATION OF VIREMIA AND NEUTRALIZING ANTIBODY TYPE I INTERFERON-ASSOCIATED GENE EXPRESSION PREDICTS TIME TO VIRAL REBOUND ON TI Joana Dias Penny Zacharopoulou IMMUNE CORRELATES OF POSTTREATMENT CONTROL IN SHIV-INFECTED INFANT MACAQUES Jana L. Jacobs Veronica Obregon-Perko CHARACTERIZATION AND EPITOPE MAPPING OF SARS-CoV-2–SPECIFIC T CELLS HIV-1 PROVIRUS CANNOT BE REACTIVATED IN PATIENTS ON TREATMENT WITH ART AND DASATINIB SIV∆GY INFECTION INDUCES ELITE CONTROL AND RESISTANCE TO SHIV HETEROLOGOUS CHALLENGE Kristin L. Boswell Mayte Coiras Susan Pereira Ribeiro BARICITINIB LOWERS INFLAMMATION AND PATHOLOGY IN SARS-CoV-2–INFECTED RHESUS MACAQUES DURABLE HIV-1 ANTIBODY PRODUCTION IN HUMANS AFTER AAV8-MEDIATED GENE TRANSFER TRAPPING THE HIV-1 V3 LOOP IN A HELICAL CONFORMATION ENABLES BROAD NEUTRALIZATION Timothy Hoang Joseph P. Casazza Matthias Glögl ONE DOSE OF COVID-19 mRNA VACCINE IN SARS-CoV-2–EXPERIENCED PEOPLE MAY BE SUFFICIENT A PLACEBO-CONTROLLED ATI TRIAL OF HTI VACCINES IN EARLY TREATED HIV INFECTION AN Env-gag mRNA VACCINE PROTECTS MACAQUES FROM HETEROLOGOUS TIER-2 SHIV INFECTION Mark Mulligan Beatriz Mothe Peng Zhang SARS-CoV-2 RECRUITS A HAEM METABOLITE TO EVADE ANTIBODY IMMUNITY O-11 BRAIN CONNECTIONS, MALIGNANCIES, AND TUMOR VIRUSES O-2 HIV TREATMENT AND PREVENTION: NEW OPPORTUNITIES TO OPTIMIZE DRUG DOSING, ADHERENCE, AND Annachiara Rosa Oral Abstract Moderators: Dennis L. Kolson and Ronald T. Mitsuyasu ANTIRETROVIRAL THERAPY O-6 NEW WEAPONS AGAINST SARS-CoV-2 AND HIV NEURON DAMAGE AND RESERVOIR ARE SECONDARY TO HIV TRANSCRIPTS DESPITE SUPPRESSIVE ART Oral Abstract Moderators: Angela Kashuba and Courtney V. Fletcher Oral Abstract Moderators: Kazuo Suzuki ISLATRAVIR PK THRESHOLD & DOSE SELECTION FOR MONTHLY ORAL HIV-1 PrEP Joseph J. Eron and Douglas D. Richman 3T BRAIN MRS REVEALS DISTINCT METABOLITE PATTERNS OF ART INITIATION DURING ACUTE HIV Munjal Patel BAMLANIVIMAB PREVENTS COVID-19 MORBIDITY AND MORTALITY IN NURSING-HOME SETTING Napapon Sailasuta NEXT-GENERATION ISLATRAVIR IMPLANTS PROJECTED TO PROVIDE YEARLY HIV PROPHYLAXIS Myron S. Cohen EFFECTS OF HIV AND AGING ON FUNCTIONAL CONNECTIVITY AND ANATOMY Randolph P. Matthews BAMLANIVIMAB+ETESEVIMAB FOR TREATMENT OF COVID-19 IN HIGH-RISK AMBULATORY PATIENTS Patrick H. Luckett CLINICAL EVALUATION OF DRUG INTERACTIONS WITH ORAL LENACAPAVIR AND PROBE DRUGS Michael Dougan DIVERGENT AND SELF-REACTIVE IMMUNE RESPONSES IN THE CNS OF COVID-19 PATIENTS Justin Lutz CASIRIVIMAB WITH IMDEVIMAB ANTIBODY COCKTAIL FOR COVID-19 PREVENTION: INTERIM RESULTS Shelli F. Farhadian PK AND SAFETY OF HIGH-DOSE RIFAMPICIN IN TB/HIV COINFECTED PATIENTS ON EFV OR DTG Meagan P. O'Brien CHROMOSOMAL COPY NUMBER ALTERATIONS IN ANAL PRECANCERS FROM PEOPLE WITH HIV Christine Sekaggya-Wiltshire POTENT NEUTRALIZING ANTIBODIES FOR SEVERE COVID-19: A RANDOMIZED CLINICAL TRIAL Tinaye Mutetwa PK OF DOSE-ADJUSTED EMERGENCY CONTRACEPTION WITH EFV-BASED ART IN ACTG 5375 Carlijn Jordans POMALIDOMIDE AND LIPOSOMAL DOXORUBICIN FOR KAPOSI SARCOMA +/– OTHER KSHV DISEASES Kimberly K. Scarsi ESTIMATING WITHIN-HOST R0 FOR SARS-CoV-2 AND IMPLICATIONS FOR ANTIVIRAL THERAPY Ramya Ramaswami EMTRICITABINE TRIPHOSPHATE IN DRIED BLOOD SPOTS PREDICTS FUTURE VIREMIA IN PWH Ruian Ke VAGINAL pH PREDICTS CERVICAL INTRAEPITHELIAL NEOPLASIA-2 REGRESSION IN HIV+ WOMEN Jose R. Castillo-Mancilla PHASE IIA PROOF-OF-CONCEPT TRIAL OF NEXT-GENERATION MATURATION INHIBITOR GSK3640254 Katherine G. Michel TENOFOVIR DIPHOSPHATE TO PREDICT FUTURE VIRAEMIA IN POSTPARTUM WOMEN LIVING WITH HIV Christoph Spinner WILMS' TUMOR 1 IS OVEREXPRESSED IN KAPOSI SARCOMA AND IS REGULATED BY VFLIP/K13 Jasantha Odayar POTENT ANTIVIRAL ACTIVITY OF LENACAPAVIR IN PHASE 2/3 IN HEAVILY ART-EXPERIENCED PWH Ayana Morales NUCLEOSIDES AND DARUNAVIR/DOLUTEGRAVIR IN AFRICA (NADIA) TRIAL: 48WKS PRIMARY OUTCOME Sorana Segal-Maurer INFLAMMASOME ACTIVATION IN PATIENTS WITH KSHV-ASSOCIATED DISORDERS Nicholas Paton ACTIVITY AND RESISTANCE HARACTERIZATION OF THE HIV CAPSID INHIBITOR LENACAPAVIR Ramya Ramaswami RANDOMIZED TRIAL OF RESISTANCE TESTING FOR VIROLOGIC FAILURE IN SUB-SAHARAN AFRICA Laurie VanderVeen O-12 MATERNAL AND CHILD HIV AND SARS-CoV-2 Mark Siedner RESISTANCE PROFILE OF MK-8507, A NOVEL NNRTI SUITABLE FOR WEEKLY ORAL HIV TREATMENT Oral Abstract Moderators: Landon Myer and Hermione Lyall O-3 COMPLICATIONS OF HIV AND COVID-19 Tracy L. Diamond COVID-19 INFECTION IN HIGH-RISK SOUTH AFRICAN PREGNANCIES WITH AND WITHOUT HIV Oral Abstract Moderators: Judith S. Currier and Peter W. Hunt O-7 TUBERCULOSIS AND HEPATITIS Liesl De Waard SHORT-COURSE ALENDRONATE FOR THE PREVENTION OF ART-ASSOCIATED BONE LOSS Oral
Recommended publications
  • Glycan Clustering Stabilizes the PRITCHARD Online 13May2015 GREEN

    Glycan Clustering Stabilizes the PRITCHARD Online 13May2015 GREEN

    King’s Research Portal DOI: 10.1038/ncomms8479 Document Version Peer reviewed version Link to publication record in King's Research Portal Citation for published version (APA): Pritchard, L. K., Spencer, D. I. R., Royle, L., Bonomelli, C., Seabright, G. E., Behrens, A-J., Kulp, D. W., Menis, S., Krumm, S. A., Dunlop, D. C., Crispin, D. J., Bowden, T. A., Scanlan, C. N., Ward, A. B., Schief, W. R., Doores, K. J., & Crispin, M. (2015). Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies. Nature Communications, 6(1), [7479]. https://doi.org/10.1038/ncomms8479 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
  • What Immune Responses to the Coronavirus Say

    What Immune Responses to the Coronavirus Say

    Feature KTDESIGN/SPL Immunologists are on the hunt for the antibodies (and B cells and T cells) that help to defeat SARS-CoV-2 in the body. with uncommon speed, determined which are likely to be the most effective, and designed WHAT IMMUNE RESPONSES TO vaccines and therapies that, in animal stud- ies and small-scale human studies, provoke at THE CORONAVIRUS SAY ABOUT least short-term immune responses. But there is no quick and simple experiment that can PROSPECTS FOR A VACCINE firmly determine whether immunity will be effective or lasting. It is just too soon to know. Viral immunologists say that results so far have “Only the future can tell us,” says Reinhold Förster, an immunologist at the Hanover been predictable — here’s why that’s good news. Medical School in Germany. By Heidi Ledford Sporadic accounts of reinfection — people recovering from COVID-19, only to fall ill and test positive for the virus again — have stoked fears that immunity might be short-lived. On n the late 1980s, 15 healthy people moved before their immune systems could launch 24 August, news broke of a man in Hong Kong into new apartments in Salisbury, UK. On an effective defence1. who had been infected twice, with genetically their third day, each was asked to snort It was an early hint of the answer to a question distinct variants of SARS-CoV-2, although he a nostril-ful of solution containing a that now keeps researchers, physicians and showed no symptoms the second time. It is the coronavirus — one of several viruses that politicians alike awake at night: can the human best-documented case of reinfection so far.

  • Croi 2021 Program Committee

    General Information CONTENTS WELCOME . 2 General Information General Information OVERVIEW . 2 CONTINUING MEDICAL EDUCATION . 3 CONFERENCE SUPPORT . 4 VIRTUAL PLATFORM . 5 ON-DEMAND CONTENT AND WEBCASTS . 5 CONFERENCE SCHEDULE AT A GLANCE . 6 PRECONFERENCE SESSIONS . 9 LIVE PLENARY, ORAL, AND INTERACTIVE SESSIONS, AND ON-DEMAND SYMPOSIA BY DAY . 11 SCIENCE SPOTLIGHTS™ . 47 SCIENCE SPOTLIGHT™ SESSIONS BY CATEGORY . 109 CROI FOUNDATION . 112 IAS–USA . 112 CROI 2021 PROGRAM COMMITTEE . 113 Scientific Program Committee . 113 Community Liaison Subcommittee . 113 Former Members . 113 EXTERNAL REVIEWERS . .114 SCHOLARSHIP AWARDEES . 114 AFFILIATED OR PROXIMATE ACTIVITIES . 114 EMBARGO POLICIES AND SOCIAL MEDIA . 115 CONFERENCE ETIQUETTE . 115 ABSTRACT PROCESS Scientific Categories . 116 Abstract Content . 117 Presenter Responsibilities . 117 Abstract Review Process . 117 Statistics for Abstracts . 117 Abstracts Related to SARS-CoV-2 and Special Study Populations . 117. INDEX OF SPECIAL STUDY POPULATIONS . 118 INDEX OF PRESENTING AUTHORS . .122 . Version 9 .0 | Last Update on March 8, 2021 Printed in the United States of America . © Copyright 2021 CROI Foundation/IAS–USA . All rights reserved . ISBN #978-1-7320053-4-1 vCROI 2021 1 General Information WELCOME TO vCROI 2021 Welcome to vCROI 2021! The COVID-19 pandemic has changed the world for all of us in so many ways . Over the past year, we have had to put some of our HIV research on hold, learned to do our research in different ways using different tools, to communicate with each other in virtual formats, and to apply the many lessons in HIV research, care, and community advocacy to addressing the COVID-19 pandemic . Scientists and community stakeholders who have long been engaged in the endeavor to end the epidemic of HIV have pivoted to support and inform the unprecedented progress made in battle against SARS-CoV-2 .
  • Remdesivir for the Treatment of Covid-19 — Preliminary Report

    Remdesivir for the Treatment of Covid-19 — Preliminary Report

    The new england journal of medicine Original Article Remdesivir for the Treatment of Covid-19 — Preliminary Report J.H. Beigel, K.M. Tomashek, L.E. Dodd, A.K. Mehta, B.S. Zingman, A.C. Kalil, E. Hohmann, H.Y. Chu, A. Luetkemeyer, S. Kline, D. Lopez de Castilla, R.W. Finberg, K. Dierberg, V. Tapson, L. Hsieh, T.F. Patterson, R. Paredes, D.A. Sweeney, W.R. Short, G. Touloumi, D.C. Lye, N. Ohmagari, M. Oh, G.M. Ruiz-Palacios, T. Benfield, G. Fätkenheuer, M.G. Kortepeter, R.L. Atmar, C.B. Creech, J. Lundgren, A.G. Babiker, S. Pett, J.D. Neaton, T.H. Burgess, T. Bonnett, M. Green, M. Makowski, A. Osinusi, S. Nayak, and H.C. Lane, for the ACTT-1 Study Group Members*​​ ABSTRACT BACKGROUND Although several therapeutic agents have been evaluated for the treatment of coro- The authors’ full names, academic de- navirus disease 2019 (Covid-19), none have yet been shown to be efficacious. grees, and affiliations are listed in the Ap- pendix. Address reprint requests to Dr. METHODS Beigel at the National Institute of Allergy and Infectious Diseases, National Insti- We conducted a double-blind, randomized, placebo-controlled trial of intravenous tutes of Health, 5601 Fishers Ln., Rm. remdesivir in adults hospitalized with Covid-19 with evidence of lower respiratory 7E60, MSC 9826, Rockville, MD 20892- tract involvement. Patients were randomly assigned to receive either remdesivir 9826, or at jbeigel@ niaid . nih . gov. (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional *A complete list of members of the ACTT-1 Study Group is provided in the days) or placebo for up to 10 days.
  • Supplementary Appendix

    Supplementary Appendix

    Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Swindells S, Andrade-Villanueva J-F, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med 2020;382:1112-23. DOI: 10.1056/NEJMoa1904398 (PDF updated March 26, 2020) Susan Swindells, et al. Long-Acting Cabotegravir and Rilpivirine for HIV-1 (ATLAS Trial) SUPPLEMENTARY APPENDIX Contents Study Sites and Lead Investigators ............................................................................................................... 2 Eligibility Criteria ........................................................................................................................................... 6 Figure S1. Timeliness of Injections Relative to Target. ............................................................................... 14 Figure S2. Unadjusted Difference (LA Arm Minus CAR Arm) in Percentage Proportion with HIV-1 RNA ≥50 copies/mL at Week 48 (Snapshot) ± 95% CI. ............................................. 15 Figure S3. Incidence of Injection Site Reaction Adverse Events, LA Arm.................................................... 16 Table S1. Summary of Antiretroviral Agents Taken at Baseline. ................................................................ 17 Table S2. Reasons for Exclusion From the Per-Protocol Population .......................................................... 18 Table S3. Additional Secondary Endpoints ................................................................................................
  • Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know Jinoos Yazdany, MD, MPH, and Alfred H.J

    Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know Jinoos Yazdany, MD, MPH, and Alfred H.J

    Annals of Internal Medicine IDEAS AND OPINIONS Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know Jinoos Yazdany, MD, MPH, and Alfred H.J. Kim, MD, PhD n the desperate search to find effective treatments mediated diseases is not. For example, HCQ is a Ifor coronavirus disease 2019 (COVID-19), 2 generic cornerstone of therapy for SLE. Hydroxychloroquine drugs, used largely by rheumatologists and dermatolo- can effectively treat disease manifestations, such as gists to treat immune-mediated diseases, have entered joint pain and rashes; reduce thrombotic events; and the spotlight. The antimalarials hydroxychloroquine prolong survival. Of note, landmark clinical trials have (HCQ) and chloroquine (CQ) have demonstrated anti- demonstrated that the withdrawal of HCQ can lead to viral activity against severe acute respiratory syndrome– flares of disease, including life-threatening manifesta- coronavirus 2 (SARS–CoV-2) in vitro and in small, poorly tions, such as lupus nephritis (8). The current shortages controlled or uncontrolled clinical studies (1–3). Nor- of HCQ have therefore alarmed rheumatologists and mally, such research would be deemed hypothesis- patients. Offices across the country report fielding calls generating at best. A tweet by President Trump on 21 from concerned patients who are having difficulty ob- March 2020 claiming that the combination of HCQ and taining their medication. azithromycin “ha[s] a real chance to be one of the big- Given the likelihood that shortages will continue in gest game changers in the history of medicine” accel- the near term, we propose that manufacturers, clini- erated a worldwide run on the drugs, with pharmacies cians, pharmacies, health systems, and governmental reporting shortages within 24 hours.
  • Longitudinal Observation and Decline of Neutralizing Antibody Responses in the Three Months Following SARS-Cov-2 Infection in Humans

    Longitudinal Observation and Decline of Neutralizing Antibody Responses in the Three Months Following SARS-Cov-2 Infection in Humans

    ARTICLES https://doi.org/10.1038/s41564-020-00813-8 Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans Jeffrey Seow 1,8, Carl Graham1,8, Blair Merrick 2,8, Sam Acors 1,8, Suzanne Pickering 1, Kathryn J. A. Steel3, Oliver Hemmings4, Aoife O’Byrne3, Neophytos Kouphou1, Rui Pedro Galao 1, Gilberto Betancor1, Harry D. Wilson 1, Adrian W. Signell 1, Helena Winstone1, Claire Kerridge1, Isabella Huettner1, Jose M. Jimenez-Guardeño 1, Maria Jose Lista1, Nigel Temperton 5, Luke B. Snell 2, Karen Bisnauthsing2, Amelia Moore6, Adrian Green6, Lauren Martinez 6, Brielle Stokes 6, Johanna Honey6, Alba Izquierdo-Barras 6, Gill Arbane7, Amita Patel 2, Mark Kia Ik Tan 2, Lorcan O’Connell2, Geraldine O’Hara 2, Eithne MacMahon2, Sam Douthwaite2, Gaia Nebbia2, Rahul Batra2, Rocio Martinez-Nunez1, Manu Shankar-Hari 1,7, Jonathan D. Edgeworth1,2, Stuart J. D. Neil1, Michael H. Malim 1 and Katie J. Doores 1 ✉ Antibody responses to SARS-CoV-2 can be detected in most infected individuals 10–15 d after the onset of COVID-19 symptoms. However, due to the recent emergence of SARS-CoV-2 in the human population, it is not known how long antibody responses will be maintained or whether they will provide protection from reinfection. Using sequential serum samples collected up to 94 d post onset of symptoms (POS) from 65 individuals with real-time quantitative PCR-confirmed SARS-CoV-2 infection, we show seroconversion (immunoglobulin (Ig)M, IgA, IgG) in >95% of cases and neutralizing antibody responses when sampled beyond 8 d POS.
  • Supplementary Appendix

    Supplementary Appendix

    Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — final report. N Engl J Med. DOI: 10.1056/NEJMoa2007764 Supplementary Appendix to Manuscript Entitled Remdesivir for the Treatment of COVID-19 – Final Report Table of Contents: ACTT-1 Study Group ...................................................................................................................... 3 ACTT-1 Study Team Members ....................................................................................................... 8 Supplemental Methods: ................................................................................................................. 17 Additional Study Design Details ............................................................................................... 17 Additional Study population Details ......................................................................................... 17 Additional Study Procedures Details ........................................................................................ 18 Additional Statistical Analysis Details ...................................................................................... 19 Supplemental Tables and Figures: ................................................................................................ 20 Table S1. Categorical Demographic and Baseline Characteristics by Treatment Group ......... 20 Table

  • 1 CAPRI Adaptive Protocol Ver 3.0 7/26/2020 a Randomized Controlled

    A randomized controlled adaptive study comparing COVID-19 convalescent plasma to non-immune plasma to limit coronavirus-associated complications in hospitalized patients. IND # 21774 Protocol Chairs: Annie Luetkemeyer & Priscilla Hsue Version 3.0 7/26/2020 1 CAPRI Adaptive protocol Ver 3.0 7/26/2020 A randomized, controlled, adaptive study comparing COVID-19 convalescent plasma to non-immune plasma to limit coronavirus-associated complications in hospitalized patients. SIGNATURE PAGE I will conduct the study in accordance with the provisions of this protocol and all applicable protocol-related documents. I agree to conduct this study in compliance with United States (US) Health and Human Service regulations (45 CFR 46); applicable U.S. Food and Drug Administration regulations; standards of the International Conference on Harmonization Guideline for Good Clinical Practice (E6); Institutional Review Board/Ethics Committee determinations; all applicable in-country, state, and local laws and regulations; and other applicable requirements and institutional policies. Principal Investigator: _______________________________________________ Print/Type Signed: ___________________________________ Date: _____________ Name/Title 2 CAPRI Adaptive protocol Ver 3.0 7/26/2020 Contents 1 PROTOCOL TEAM ROSTER ............................................................................................................................................... 5 2 LIST OF ABBREVIATIONS ................................................................................................................................................
  • Meeting of the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment November 16-17, 2016 Rockville, Maryland

    Meeting of the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment November 16-17, 2016 Rockville, Maryland

    U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR DISEASE CONTROL AND PREVENTION HEALTH RESOURCES AND SERVICES ADMINISTRATION Meeting of the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment November 16-17, 2016 Rockville, Maryland Record of the Proceedings TABLE OF CONTENTS Agenda Item Page MINUTES OF THE NOVEMBER 16-17, 2016 CHAC MEETING 1 Opening Session: November 16, 2016 2 Update by the Acting HRSA Administrator 5 HRSA/HAB Associate Administrator’s Report 8 CDC/NCHHSTP Director’s Report 13 People Living with HIV Leadership 20 PANEL PRESENTATION: ELIMINATING HCV 25 • Update on the 2017-2020 National Viral Hepatitis Action Plan 25 • CMS’s Role in the National Viral Hepatitis Response 27 • Overview of the San Francisco HCV Elimination Initiative 29 • Overview of the New Mexico HCV Elimination Collaborative 32 • Overview of NASTAD’s Technical Assistance for HIV/HCV Co-Infection 36 CDC New Surveillance Report ─ Changes in Analyzing the HIV Care Continuum 39 PANEL PRESENTATION: CMS, CDC, HRSA HIV HEALTH IMPROVEMENT AFFINITY 42 GROUP Public Comment Period 49 Update by the CHAC Viral Hepatitis Workgroup 51 Preparation for the CHAC Business Session 54 Opening Session: November 17, 2016 55 Leveraging Partnerships to Support Increased Employment/Educational 56 Opportunities for PLWH PANEL PRESENTATION: HIV AND AGING ─ IMPLICATIONS FOR HEALTH CARE, 60 MENTAL HEALTH, AND SUPPORT NEEDS Update by the CHAC Pre-Exposure Prophylaxis Workgroup 67 CHAC Business Session 70 • TOPIC 1: APPROVAL OF THE JUNE 2016 DRAFT CHAC MEETING MINUTES 70 • TOPIC 2: ESTABLISHMENT OF A NEW CHAC YOUTH WORKGROUP 70 • TOPIC 3: ESTABLISHMENT OF A NEW CHAC HIV AND AGING WORKGROUP 71 • TOPIC 4: DRAFT HCV RESOLUTION 72 • TOPIC 5: WORKFORCE DEVELOPMENT 76 • TOPIC 6: FUTURE AGENDA ITEMS 78 Closing Session 80 Attachment 1: Participants’ Directory 82 Attachment 2: Glossary of Acronyms 85 U.S.
  • A Computational Approach to Aid Clinicians in Selecting Anti-Viral Drugs for COVID-19 Trials

    A Computational Approach to Aid Clinicians in Selecting Anti-Viral Drugs for COVID-19 Trials

    A computational approach to aid clinicians in selecting anti-viral drugs for COVID-19 trials Aanchal Mongia1, Sanjay Kr. Saha2, Emilie Chouzenoux3∗ & Angshul Majumdar4∗ 1Dept. of CSE, IIIT - Delhi, India, 110020 2Department of Community Medicine, IPGMER Kolkata 3CVN, Inria Saclay, Univ. Paris Saclay, 91190 Gif-sur-Yvette, France 4Dept. of ECE, IIIT - Delhi, India, 110020 ∗Corresponding authors contact/Email: [email protected], [email protected] 3 July, 2020 Abstract Motivation: COVID-19 has fast-paced drug re-positioning for its treatment. This work builds computational models for the same. The aim is to assist clinicians with a tool for selecting prospective antiviral treatments. Since the virus is known to mutate fast, the tool is likely to help clinicians in selecting the right set of antivirals for the mutated isolate. Results: The main contribution of this work is a manually curated database publicly shared, comprising of existing associations between viruses and their corresponding antivirals. The database gathers similarity information using the chemical structure of drugs and the genomic structure of viruses. Along with this database, we make available a set of state-of-the-art computational drug re-positioning tools based on matrix completion. The tools are first analysed on a standard set of experimental protocols for drug target interactions. The best performing ones are applied for the task of re-positioning antivirals for COVID-19. These tools select six drugs out of which four are currently under various stages of trial, namely Remdesivir (as a cure), Ribavarin (in combination with others for cure), Umifenovir (as a prophylactic and cure) and Sofosbuvir (as a cure).
  • S41564-020-00813-8.Pdf

    S41564-020-00813-8.Pdf

    Kent Academic Repository Full text document (pdf) Citation for published version Seow, Jeffrey and Graham, Carl and Merrick, Blair and Acors, Sam and Pickering, Suzanne and Steel, Kathryn J. A. and Hemmings, Oliver and O’Byrne, Aoife and Kouphou, Neophytos and Galao, Rui Pedro and Betancor, Gilberto and Wilson, Harry D. and Signell, Adrian W. and Winstone, Helena and Kerridge, Claire and Huettner, Isabella and Jimenez-Guardeño, Jose M. and Lista, DOI https://doi.org/10.1038/s41564-020-00813-8 Link to record in KAR https://kar.kent.ac.uk/83758/ Document Version Publisher pdf Copyright & reuse Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions for further reuse of content should be sought from the publisher, author or other copyright holder. Versions of research The version in the Kent Academic Repository may differ from the final published version. Users are advised to check http://kar.kent.ac.uk for the status of the paper. Users should always cite the published version of record. Enquiries For any further enquiries regarding the licence status of this document, please contact: [email protected] If you believe this document infringes copyright then please contact the KAR admin team with the take-down information provided at http://kar.kent.ac.uk/contact.html ARTICLES https://doi.org/10.1038/s41564-020-00813-8 Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans Jeffrey Seow 1,8, Carl Graham1,8, Blair Merrick 2,8, Sam Acors 1,8, Suzanne Pickering 1, Kathryn J.